Sanofi-Aventis SA said that its offer for Genzyme Corp has been accepted by shareholders representing 84.6% of the company’s common stock and approximately 77% of shares on a fully-diluted basis, giving the French company full control.
Algeta ASA and Genzyme Corp (Sanofi-Aventis) have announced plans to jointly explore the use of the Norwegian company’s radiopharmaceutical platform to enhance the ability of a Genzyme monoclonal antibody to target and kill cancer.
Patients who received tissue-engineered implants to correct for defects in their urethras reported normal functioning of their urethras for up to six years after surgery, according to an observational study in The Lancet.
Acacia Pharma Ltd, which specialises in drugs for cancer supportive care, has raised $10 million in a Series A financing round supported by the new investor, Lundbeckfond Ventures. Gilde Healthcare also participated in the round.
Newron Pharmaceuticals SpA has reached a licensing agreement with Merck Serono to investigate the potential of two Merck clinical-stage compounds for disorders of the central nervous system. Financial terms weren’t disclosed.
A Phase-3 study of motesanib, a small molecule antagonist of vascular endothelial growth factor (VEGF) receptors, failed to meet its primary endpoint of improving the overall survival for patients with advanced, non-squamous, non-small cell lung cancer (NSCLC), the sponsor said.
Anergis SA, a privately held Swiss company developing immunotherapy for allergies, has received an endorsement of its technology with a CHF18 million (€14 million) Series “A” venture financing.
The US Food and Drug Administration has approved a new monoclonal antibody, Yervoy (ipilimumab), to treat patients with late-stage melanoma, the most dangerous type of skin cancer. The antibody is manufactured by Bristol-Myers Squibb Inc.
Paion AG more than doubled its revenue in 2010 as a result of milestone payments from three partners relating to progress in the development of desmoteplase for stroke; remimazolam for sedation and glial growth factor 2 (GGF2) for heart failure.
Evotec AG reported both operating and net profits for 2010, the first time in the company’s 18-year history, as it started to reap the rewards of a strategic shift towards drug discovery alliances with other companies instead of solo development.